Mupirocin
From Pharmacopedia
More actions
Mupirocin
Bactroban, Centany
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Common uses
Impetigo0, Localized superficial skin infections (folliculitis, secondarily infected dermatitis)0, MRSA nasal decolonization (pre-operative or institutional outbreaks)0
Pharmacy
Starting dose
Topical: apply small amount to affected area TID × 5-10 days; nasal: apply half the contents of a single-use tube into each nostril BID × 5 days
Preparations
2% ointment; 2% cream; 2% nasal ointment (Bactroban Nasal)
US FDA Max
Limit topical to 10-day courses to reduce resistance pressure
Pharmacology
Routes
Topical, intranasal
Onset
Days
Duration
Hours per application
Half-life
Not meaningfully described for topical use[1]
Bioavailability
Topical; minimal systemic absorption[1]
Pregnancy
Generally considered safe; minimal systemic exposure.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Mupirocin (pseudomonic acid A) binds bacterial isoleucyl-tRNA synthetase, blocking incorporation of isoleucine into bacterial proteins and arresting protein synthesis; the human counterpart enzyme is sufficiently different that there is no cross-reactivity.0 Active against gram-positive cocci including MRSA; the unique target underlies the absence of cross-resistance with other antibiotic classes. High-level resistance (plasmid-mediated mupA) is rising and limits prolonged or repeated use[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Bactroban (mupirocin), GlaxoSmithKline, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050591s029,050595s022lbl.pdf